MAGE-A4-TCB: Translational Strategy for TCR-Based Therapy Safety Assessment

A 2026 figshare publication by Angelique Augustin details a translational safety strategy for the first-in-human study of the MAGE-A4-TCB T cell bispecific antibody. The 28.7 MB PDF describes the use of 21 human cellular systems and 22 tumor organoids to establish a safe starting dose, which was validated in a subsequent Phase I clinical trial (NCT05129280).

Use Cases

• Benchmarking in vitro safety assessment methodologies based on the described use of 21 human cellular systems.
• Analyzing cytokine release syndrome risk prediction based on the whole blood assay methodology detailed in the description.
• Studying translational frameworks for TCR-based immunotherapies based on the described approach from nonclinical testing to Phase I study.
• Investigating skin-related adverse event mechanisms in immunotherapy based on the reported clinical findings of treatment-related skin disorders in 73% of patients.

Strengths

• Provides a detailed case study referencing a specific Phase I clinical trial (NCT05129280).
• Describes a concrete methodological approach using 21 human cellular systems and 22 tumor organoids.
• Includes specific clinical outcome data, such as skin-related adverse events affecting 73% of patients.

Limitations

• The primary data content is a PDF document; underlying experimental datasets are not directly accessible.
• Row count and column-level documentation for any underlying data are unknown.
• The methodology's predictive accuracy for complex systemic adverse events is noted as an area needing refinement.

Provenance

Source

figshare, authored by Angelique Augustin.

Collection Method

Describes a translational research strategy combining in vitro models and clinical trial data.

Time Range

Publication date is 2026; clinical trial referenced is ongoing or recent.

Freshness

Last updated 2026-04-17 08:51:06.

Geography

null